Millstone Evans Group’s Maravai LifeSciences MRVI Stock Holding History

Millstone Evans Group’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01K	Hold	162	–	–	﹤0.01%	822
2026 Q1	$458	Hold	162	–	–	﹤0.01%	833
2025 Q4	$527	Hold	162	–	–	﹤0.01%	834
2025 Q3	$465	Hold	162	–	–	﹤0.01%	818
2025 Q2	$390	Hold	162	–	–	﹤0.01%	750
2025 Q1	$358	Hold	162	–	–	﹤0.01%	778
2024 Q4	$883	Buy	+162	New	+$1.04K	﹤0.01%	691

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Millstone Evans Group's MRVI Position: Q2 2026 in Review

Millstone Evans Group held its Maravai LifeSciences (MRVI) position steady in Q2 2026 at 162 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #822.

Millstone Evans Group first reported a position in MRVI in Q4 2024 and has held it in 7 quarters since. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Millstone Evans Group held 162 shares of Maravai LifeSciences worth $1.01K as of Q2 2026.
Millstone Evans Group left its Maravai LifeSciences share count unchanged in Q2 2026.
Maravai LifeSciences made up ﹤0.01% of Millstone Evans Group's portfolio in Q2 2026, its #822 holding.
Millstone Evans Group first reported a position in Maravai LifeSciences in Q4 2024 and has held it in 7 quarters since.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.